145 related articles for article (PubMed ID: 8842923)
1. Antibiotic use in the emergency department. III. The quinolones, new beta lactams, beta lactam combination agents, and miscellaneous antibiotics.
Schmidt J; Pollack CV
J Emerg Med; 1996; 14(4):483-96. PubMed ID: 8842923
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
3. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
Rotschafer JC; Ostergaard BE
Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
[TBL] [Abstract][Full Text] [Related]
4. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
Piddock LJ; Jin YF; Turner HL
J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
[TBL] [Abstract][Full Text] [Related]
5. β-lactam/β-lactamase inhibitor combinations: from then to now.
Toussaint KA; Gallagher JC
Ann Pharmacother; 2015 Jan; 49(1):86-98. PubMed ID: 25361682
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of the anaerobic gram-negative non-sporulating rod, Bilophila wadsworthia to beta-lactams, beta-lactamase inhibitors, meropenem, metronidazole, clindamycin and quinolones.
Schumacher UK; Single B
Zentralbl Bakteriol; 1998 May; 287(4):421-5. PubMed ID: 9638871
[TBL] [Abstract][Full Text] [Related]
7. Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides.
Joly-Guillou ML; Decré D; Herrman JL; Bourdelier E; Bergogne-Bérézin E
J Antimicrob Chemother; 1995 Oct; 36(4):619-29. PubMed ID: 8591936
[TBL] [Abstract][Full Text] [Related]
8. [Pseudomonas aeruginosa: bactericidal activity on various beta-lactam resistance phenotypes of 8 antibiotics and 7 combinations].
Dubrous P; Cavallo JD; Hernandez E; Nordmann P; Fabre R
Pathol Biol (Paris); 1997 May; 45(5):433-7. PubMed ID: 9296099
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of beta-lactam/beta-lactamase inhibitor combinations.
García-Rodríguez JA; García Sánchez JE; García García MI; García Sánchez E; Muñoz Bellido JL
Diagn Microbiol Infect Dis; 1991; 14(3):239-43. PubMed ID: 1889176
[TBL] [Abstract][Full Text] [Related]
10. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
Vanjak D; Muller-Serieys C; Picard B; Bergogne-Berezin E; Lambert-Zechovsky N
Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
[TBL] [Abstract][Full Text] [Related]
11. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection.
Powell LL; Wilson SE
Surg Infect (Larchmt); 2000; 1(1):57-63. PubMed ID: 12594910
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa.
McLaughlin JC; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; Pfaller MA
J Antimicrob Chemother; 1994 Feb; 33(2):223-30. PubMed ID: 8182003
[TBL] [Abstract][Full Text] [Related]
13. beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.
Jacobs MR; Spangler SK; Appelbaum PC
Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1081-93. PubMed ID: 1295763
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
15. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments.
Miller LA; Ratnam K; Payne DJ
Curr Opin Pharmacol; 2001 Oct; 1(5):451-8. PubMed ID: 11764769
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of anaerobic bacteria to beta-lactam antibiotics in the United States.
Johnson CC
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S371-6. PubMed ID: 8324150
[TBL] [Abstract][Full Text] [Related]
17. Aminoglycoside resistant enterococcal endocarditis.
Eliopoulos GM
Infect Dis Clin North Am; 1993 Mar; 7(1):117-33. PubMed ID: 8463648
[TBL] [Abstract][Full Text] [Related]
18. Combating bacterial resistance in skin and skin-structure infection: importance of beta-lactamase inhibition.
Chan JC
Am J Ther; 1999 Jan; 6(1):13-8. PubMed ID: 10423642
[TBL] [Abstract][Full Text] [Related]
19. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria].
Probst-Kepper M; Geginat G
Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899
[TBL] [Abstract][Full Text] [Related]
20. Resistance of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors.
Neu HC; Saha G; Chin NX
Diagn Microbiol Infect Dis; 1989; 12(3):283-5. PubMed ID: 2791491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
